GEN - Genetic Engineering and Biotechnology News1d
Roche Genentech Innovation Center Boston Launched at Harvard’s Enterprise Research Campus
The hub has also been created to strengthen an existing relationship between Harvard and Roche that has been in place for over a decade.
BioPharma Dive1d
Roche launches new Boston center; NIH centralizes peer review
The Swiss pharma will base cardiometabolic drug research at the new Allston site. Elsewhere, AskBio advanced a gene therapy ...
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
Citing ‘sanctuary city’ status, SBA says it will close office in Boston
Other cities where SBA offices will close include Atlanta, Chicago, Denver, New York City, and Seattle, each of which the ...
MoneyWeek2d
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...
BioPharma Dive2d
Vertex’s new pain drug gets first coverage nod from major insurer
Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...
How Boston Scientific (sort of) became ‘Minnesota Scientific’
The company bearing Boston’s name has approximately 10,000 employees in Minnesota, doubling in the past 15 years. And it’s ...
Vertex’s non-opioid pain drug gets some UnitedHealth coverage
The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Signs of hiring at Boston-area life sciences companies
Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...
The Pharma Letter9d
Sionna Therapeutics’ NBD1 stabilizers hold potential for cystic fibrosis
Boston, USA-based biotech Sionna Therapeutics has recently raised $191 million through its initial public offering (IPO), marking a step forward in its efforts to develop treatments for cystic ...
Taiwan News10d
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the fourth quarter and full year ended December 31, 2024 and highlighted recent ...